Project Grant R43CA281387
Award Date
9/19/23
Completion Date
8/31/24
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Mabswitch Inc. (MZ15MPUFBHN9)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The key objectives are to engineer partially-matched, donor-derived CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on most T-cell...
This Project Grant award, valued at $1,271,780.00, was issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to the University of Pittsburgh. The grant supports the development of small molecule adaptor drugs to reprogram a universal chimeric antigen receptor (CAR) T cell therapy for improved targeting and treatment of cancer. Specifically, the research aims to: 1) develop small molecule adaptors for targeting the universal CAR to multiple antigens,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to support the development and clinical evaluation of CTO1681, a novel compound designed to prevent and mitigate cytokine release syndrome (CRS) in recipients of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The project aims to determine the preliminary efficacy of CTO1681 in preventing or reducing CRS and immune effector...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $195,766 to Yale University to develop a mechano-transduction platform that will enhance chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The project aims to engineer force sensors to measure forces along key immune receptors, and then integrate these force transduction modules into CAR constructs to improve the specificity and safety of CAR T-cell therapies,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $402,600.00 to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key products and services to be delivered under this 5-year award include: Testing the efficacy and safety of CAR T-cells targeting the...
The federal Project Grant award R01CA292664, totaling $1,313,806.00 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development and clinical translation of advanced chimeric antigen receptor (CAR) T-cell therapies for the treatment of solid tumors. The project aims to overcome key challenges in solid tumor immunotherapy by engineering CAR T cells with enhanced functionality, including the use of a novel costimulatory domain (KITV), checkpoint...
This $1,477,396 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to develop a novel approach to enhance the efficacy and durability of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The key products and services to be delivered under this 5-year award include: Conducting two pilot clinical trials to evaluate the safety and feasibility of administering CMV-specific...
This federal Project Grant award in the amount of $513,859 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel cell-based immunotherapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The overarching goal is to generate continuously renewing CAR-expressing natural killer (NK) cells that can provide long-term, effective anti-tumor immunity. The research focuses on leveraging naturally...
The National Cancer Institute (NCI) awarded a $604,627 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Trustees of Dartmouth College in Lebanon, New Hampshire. The grant supports research to deconvolve the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity, particularly for solid tumors. The research aims to reveal individual CAR T cell differentiation trajectories, identify engineering strategies to program CAR stem cell-like...
This $1,220,394 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a multi-year research study by the Sloan-Kettering Institute for Cancer Research in New York. The project aims to provide a comprehensive molecular and clinical characterization of acute and chronic neurotoxicity following chimeric antigen receptor (CAR) T-cell therapy, an innovative cancer treatment. Key products and services to be delivered under this award include:...